Using the 4Ts and other HIT scoring systems

Heparin is a familiar injectable medicine in Australian hospitals, used for venous thromboembolism prevention, dialysis, cardiac procedures and acute coronary syndromes. It can also trigger heparin-induced thrombocytopenia, an immune reaction that may cause thrombosis despite a low platelet count. The practical challenge of how to use the 4Ts and other scoring systems for heparin-induced thrombocytopenia is not simply adding points; it is deciding when a falling count after heparin exposure demands urgent action.

Scores support judgement rather than replace it. A good assessment links every platelet value to the medication timeline, looks for competing causes, and distinguishes a low-probability pattern from one that should be treated while laboratory confirmation is pending. This matters in emergency departments, intensive care units and regional hospitals, where sepsis, line complications and recent surgery can all depress platelets.

Why timing and exposure matter

HIT is usually caused by IgG antibodies directed against platelet factor 4 and heparin. The typical first platelet fall occurs five to ten days after exposure, but earlier onset may follow recent re-exposure, and delayed reactions can occur after heparin has stopped. This immune process differs from direct anticoagulant-related platelet activation and can sustain thrombotic risk.

Clinical warning features include unexplained thrombocytopenia, new thrombosis, skin necrosis at an injection site or thrombotic symptoms around the time of heparin exposure. Intensive care, dialysis and cardiac surgery units in Melbourne, Sydney, Brisbane and other Australian centres must balance these signals against common postoperative and critical illness causes of thrombocytopenia.

The 2017 Society of Hospital Medicine meeting in Las Vegas showed how conference education can help busy clinicians build that balance. Its Hospital Medicine 2017 portal provides conference information, learning resources and professional networking opportunities for hospitalists, reflecting the broader need for concise approaches to high-risk medicines.

Building a reliable 4Ts assessment

The first 4Ts domain is thrombocytopenia. Two points are assigned when the platelet count falls by more than 50% and the nadir remains at least 100 × 10^9/L. One point covers a 30–100% fall, or a greater than 50% fall with a nadir from 70 to 100 × 10^9/L; zero points apply to a smaller decline or a nadir below 70 × 10^9/L. Use one validated local chart and document the baseline, lowest value and percentage change.

Timing is the second domain. A fall on days five to ten scores two points, day four or days eleven to fourteen scores one, and earlier or later falls score zero. These windows assume first exposure and a stable baseline. A sharp decline soon after previous heparin treatment should prompt renewed assessment, not reassurance from a low total.

New thrombosis scores two points. Skin necrosis or acute circulatory symptoms around a heparin injection site score one, while no thrombotic feature scores zero. The final domain judges other causes: no plausible explanation scores two, a possible explanation scores one and a definite alternative scores zero. This direction is easy to misread, so verify each component separately.

The totals divide into low probability at zero to three points, intermediate at four to five and high at six to eight. Intermediate results often contain false positives and require closer review rather than reflex anticoagulation. A low score is persuasive only when the platelet trend, timing and clinical context all fit. Recalculate as the count evolves rather than anchoring to the first abnormal result.

Applying the 4Ts in Australian hospitals

Start with the medication and blood count timelines. Record the last heparin dose, switches between formulations, heparin-containing line flushes and relevant device exposure; Australian laboratories commonly report platelets in × 10^9/L, so copy the trend rather than relying on one value. Search the medication chart for other causes and examine the patient for venous or arterial thrombosis.

Sepsis, disseminated intravascular coagulation, malignancy, marrow disease, drug effects, liver disease and recent transfusion can produce false-positive 4Ts assessments. Cardiac surgery and extracorporeal support make baseline and timing especially difficult. Asking whether the fall is proportional to the clinical insult, and whether it began before or after heparin, often provides more information than the total alone.

A practical workflow is to document each component, state the resulting category, record why an alternative cause was accepted or rejected, and identify when the score will be repeated. Pharmacy, haematology and the treating team should share the same timeline. In regional settings, a structured handover can support timely discussion with a tertiary centre rather than delaying action.

Adding HITEG and other decision support

The HIT Expert Group, or HITEG, score is a useful complement when the 4Ts result is intermediate or the consequences of missing HIT are substantial. It combines the timing and magnitude of platelet fall, baseline and nadir counts, thrombosis, competing explanations and previous HIT to estimate both the probability of HIT and subsequent thrombotic risk. It should be used as a validated calculator, not recreated from memory.

ASH and CHEST guidance are not separate bedside scores, but they provide decision pathways that interpret the 4Ts alongside testing and treatment. Some Australian hospitals add electronic reminders, platelet-trend alerts or local risk categories. These tools can improve consistency, but unvalidated modifications may produce misleading totals; changes to the accepted 4Ts or HITEG method belong under formal clinical governance.

Other tools should also be labelled correctly. PF4 immunoassays and functional platelet assays are diagnostic tests, not probability scores, and a hospital anticoagulation protocol is a treatment pathway rather than a prediction model. The safest comparison uses the same definitions and patient mix because performance can differ in critically ill, postoperative and dialysis populations.

Interpreting laboratory confirmation

A PF4/heparin immunoassay, often described as a PF4 ELISA, is highly sensitive but not specific. Heparin exposure and recent thrombosis can produce antibodies without clinical HIT, especially in cardiac and intensive care settings. A positive result supports the clinical assessment; by itself, it neither proves HIT nor justifies anticoagulation without a compatible platelet or thrombotic pattern.

Functional assays demonstrate antibody-mediated platelet activation and are more specific, but access and turnaround vary. Major centres in Melbourne, Sydney and Brisbane may involve platelet immunology expertise, while hospitals elsewhere can require interstate send-away testing. Early liaison with haematology, laboratory medicine and the referral laboratory can prevent unnecessary repeats and clarify which result is needed before treatment changes.

In a low-probability case, a negative PF4 assay usually argues against HIT, yet the platelet trend still needs surveillance if exposure continues or the picture changes. In an intermediate or high case, an assay result should not delay management when thrombosis is present. Local guidance from haematology, Therapeutic Guidelines and current Australian Prescriber reviews should be reconciled with the institution’s laboratory pathway.

Converting probability into safe management

The first management decision is exposure. When HIT is suspected, stop therapeutic and prophylactic heparin, including heparin flushes, and ask pharmacy and the procedural team to identify heparin-coated devices. Changing from one heparin product to another does not resolve suspected HIT, while continuing heparin during an active immune response can increase risk.

A low-probability score usually supports stopping heparin and closely monitoring the platelet trend rather than starting non-heparin anticoagulation. An intermediate score calls for prompt reassessment, review of competing causes and early specialist input. A high-probability score, or an intermediate score with new thrombosis, generally warrants therapeutic non-heparin anticoagulation while confirmatory assessment proceeds.

Argatroban and bivalirudin are important options, but availability in Australia depends on public or private hospital formularies, pharmacy stock and medicines supply arrangements. In smaller hospitals, obtaining a non-heparin agent can take time, making early involvement of the medication supply team important. Treatment should follow the local anticoagulation protocol and individual renal function, bleeding risk and indication.

Warfarin must not be started during acute HIT before platelet recovery because of the risk of venous limb gangrene. It is generally introduced after recovery, commonly to at least 150 × 10^9/L, with at least five days of overlap and until the INR is therapeutic under haematology guidance. Patients with previous HIT need a clear record, electronic alert and discharge summary directing future teams away from heparin.

Building a reliable system of care

Reliable HIT care depends on systems as much as individual knowledge. An Australian hospital pathway should align laboratory terminology, 4Ts documentation, anticoagulant supply and escalation rules. Audit cases for delayed recognition, inappropriate heparin continuation, unnecessary platelet transfusions and inconsistent documentation. Education is most useful when it uses local cases and includes the reasoning behind each decision.

Emergency response training offers a transferable model. Australian hospitals use Code Blue and medical emergency team systems for deterioration, and the conference report on simulation conference highlights illustrates how rehearsal can improve team performance. Simulation of a heparin-exposed patient with falling platelets and new thrombosis can similarly expose workflow gaps before they occur on a ward.

The enduring lesson is to connect exposure, trend, probability and action without losing clinical judgement. The 4Ts organise that thinking; HITEG and laboratory tests refine it; treatment and communication then protect the patient. The patient who needs most attention is the one in whom heparin exposure, a meaningful platelet fall and new thrombosis converge, even when another diagnosis could explain the count.